It has been recognized that the treatment of RA patients with disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) and biological drugs including TNF-α and IL-6 blockers, as well as co-stimulation inhibitors such abatacept exert beneficial effects on the metabolic profile (10). This evidence concerns the gene IL6 and rheumatoid arthritis.